The Rise and Rally of JANX
Janux Therapeutics Inc (Symbol: JANX) saw its shares soar to a remarkable new high of $17.99 on Friday, representing a significant surge of 218.41% from the 52-week low of $5.65 established on 11/10/2023. This meteoric rise signifies a bountiful harvest for investors who have held on to JANX stock for the past year, including shrewd company insiders.
Insiders’ Winning Streak
Insiders within the company have been diligently accumulating shares over the last six months, a strategic move that is now yielding lucrative returns. Notably, there have been 2 instances where insiders seized the opportunity to buy into JANX during this period.
| Purchased | Insider | Title | Shares | Price/Share | Value |
|---|---|---|---|---|---|
| 11/13/2023 | Avalon Ventures XI, L.P. | 849,854 | $5.87 | $4,988,642.98 | |
| 11/13/2023 | Tighe Reardon | Acting Chief Financial Officer | 849,854 | $5.87 | $4,988,642.98 |
| 11/13/2023 | Jay Lichter | Director | 849,854 | $5.87 | $4,988,642.98 |
Charting Success
The price action of JANX over the past year is vividly captured in the chart below, showcasing the 50-day and 200-day moving averages along with the stock’s performance.
Current Market Movement
As of Friday afternoon, JANX shares are transacting at $16.75 per share, marginally below the newly minted 52-week high.
Ten Bargains You Can Buy Cheaper Than The Insiders Did
Also see:
• Agricultural Chemicals Dividend Stocks
• Top Ten Hedge Funds Holding TROW
• PGZ Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
